^
    Back
    Association details:
    Biomarker:ABL2 fusion
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pediatric Acute Lymphoblastic Leukemia: Regimen components…For CRLF2- and ABL class kinase fusion: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + dasatinib; IT therapy: methotrexate
    Secondary therapy:
    cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase + DR6MP
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    N Engl J Med
    Title:

    Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    Published date:
    09/11/2014
    Excerpt:
    We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL....Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib.
    DOI:
    10.1056/NEJMoa1403088